Neopac sets new standards for pharmaceutical tube production

Invests in tube line for producing semi-solid and liquid forms under hygienic conditions

Neopac, a specialist developer of Polyfoil high barrier tubes, has invested CHF13.6m (€10.5bn) in a new tube line at its plant in Oberdiessbach in Switzerland that will enable it to produce approximately 60 million tubes a year for semi-solid and liquid pharmaceutical forms under hygienic conditions.

All line processes have been thoroughly documented and validated and the entire production process is permanently supervised using a live-monitoring technique.

Neopac said it made every effort to minimise risk during the implementation of the new line, which it says will benefit pharmaceutical, medical, cosmetics and dental clients alike.

Neopac invests in a new tube line in Switzerland

“We know the demands and requirements of our niche market,” said Hans Jordi, chief executive of Neopac. “Therefore we know that flawless quality and safety procedures are top priority as far as our customers are concerned.”

The company claims to have reached new levels of quality with the Polyfoil line and the tubes are manufactured in a cleanroom under hygienic conditions.

“Many competitors carry out only a certain number of processes under cleanroom conditions,” said Jordi. “With our new tube line, all of the stages are carried out in the cleanroom – from cutting and moulding the laminate through to the finished tube. Our hygiene records are on a par with those of hospital operating rooms.”

The company is producing small pharmaceutical and single-dose tubes for eye ointments, veterinary health products and other pharmaceutical applications on the new line.

Companies